What the FDA labels say about taking them together
Carbidopa and foscarbidopa/foslevodopa
Foscarbidopa/foslevodopa's FDA label of March 19, 2026 names carbidopa in its warnings and precautions section; the carbidopa label PlainMeds reads does not name foscarbidopa/foslevodopa. The foscarbidopa/foslevodopa label: “… event of a prolonged interruption, the patient should be prescribed an oral carbidopa and levodopa product until they are able to resume VYALEV.”
Check it at the source: the carbidopa FDA label on DailyMed (effective July 2, 2020, Oceanside Pharmaceuticals); the foscarbidopa/foslevodopa FDA label on DailyMed (effective March 19, 2026, AbbVie Inc.).
What does the carbidopa label say about foscarbidopa/foslevodopa?
Carbidopa's label (effective July 2, 2020) does not name foscarbidopa/foslevodopa in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Carbidopa), NDA017830 (Aton), as published by Oceanside Pharmaceuticals, effective July 2, 2020 (SPL set d5204e5e-10ef-4758-8fc6-cb710048c687), via openFDA; the full label on DailyMed
What does the foscarbidopa/foslevodopa label say about carbidopa?
Foscarbidopa/foslevodopa label, warnings and precautionsIf the cannula is removed for an infection, either a new canula should be placed at a new infusion site or, in the event of a prolonged interruption, the patient should be prescribed an oral carbidopa and levodopa product until they are able to resume VYALEV [see Dosage and Administration ( 2.4 , 2.5 )].
Source: FDA drug label (Vyalev), AbbVie Inc., effective March 19, 2026 (SPL set 28e806e4-951c-40a9-9f0c-d0929caf054c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbidopa | Foscarbidopa/foslevodopa | |
|---|---|---|
| Labeled for | Parkinson's disease | Parkinson's disease |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.536 per tablet 25 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once